Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C53397
http://purl.obolibrary.org/obo/NCIT_C53397
Preferred Name

Brivanib Alaninate
Definitions
The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.
prefLabel
Brivanib Alaninate
label
Brivanib Alaninate
PDQ_Closed_Trial_Search_ID
462556
code
C53397
Has_Target
prefixIRI
NCIT:C53397
in_subset
Display_Name
Brivanib Alaninate
Preferred_Name
Brivanib Alaninate
FDA_UNII_Code
U2Y5OFN795
Contributing_Source
CTRP
FDA
Chemical_Formula
C22H24FN5O4
Maps_To
Brivanib Alaninate
CAS_Registry
649735-63-7
NCI_Drug_Dictionary_ID
462556
Legacy Concept Name
BMS-582664
type
ALT_DEFINITION
A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
462556
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
UMLS_CUI
C1701190
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display